Protocol Ledger

NCT04231968 · Phase III · COMPLETED

A Study of AK0529 in Chinese Infants Hospitalized With RSV

Interventional Phase III clinical trial protocol NCT04231968 sponsored by Shanghai Ark Biopharmaceutical Co in Infectious Disease and Vaccines, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2020-09-22 Enrollment: 311 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04231968
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)311 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04231968
Protocol FieldVerified Registry Value
NCT IdentifierNCT04231968
Consolidated Lead SponsorShanghai Ark Biopharmaceutical Co
Therapeutic Condition CohortInfectious Disease and Vaccines
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment311 participants (ACTUAL)
Registered Start Date2020-09-22
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT04231968
Hospital Research SiteLocationSite Profile
Peking University Third HospitalBeijing, ChinaOpen Hospital Dossier ->
The First Bethune Hospital of Jilin UniversityChangchun, ChinaOpen Hospital Dossier ->
Liaocheng People's hospitalLiaocheng, ChinaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Infectious Disease and Vaccines Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI